Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSALinezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant.The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelPredicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention.Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based PharmacokinetDrug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.Drug treatments for prosthetic joint infections in the era of multidrug resistance.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic reviewSystematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.[Rational use of antibiotics].Risk factors associated with high linezolid trough plasma concentrations.Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention.Oral antibiotic therapy.Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus.Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin.Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies
P2860
Q22305769-6B899B61-E1EA-45C2-BF6F-FDCDD58DD587Q33395850-CB540310-3BC7-4109-846C-57F8DBE90EF6Q33420826-2BF434B4-1652-413E-85F4-F8F27DF00C2DQ33438834-6BDB401A-A6B8-4F26-B64B-49BF29109F12Q33797986-D518FF73-E372-410B-908A-D7A5C072857EQ36947718-D9DE6F95-C68F-497E-BA52-162F1714A473Q38087695-C30717C0-81DA-41A4-AFCA-533C970B1468Q38089918-9F04D6DF-49A4-4D42-AF2D-3938C16332C2Q38100704-6AF6B681-0D18-4AC7-902D-E1DE9ED01387Q38161471-399B125C-2D0A-42E0-9DA6-D63A0DC85744Q38241474-D35FE9E4-54E9-4003-8729-5DA5917252FCQ38372360-5E484760-09A7-4AEE-936B-F0A689F8A75FQ38604890-3B8ABE7A-20FE-4D36-99AD-2F3620769ABCQ38800556-F4689BED-8B7B-4104-A45F-2F4328FDF3C7Q38929509-98A10F36-D1DE-47F0-89F1-EC85E51C2197Q39013332-604A5597-549B-49A1-8833-1C0530D43A79Q40121784-985BCC81-7423-446C-8BB8-A51464D724F4Q40651143-F5303E6F-8A18-4672-984C-7E6451E9F3A9Q40683242-1ED3D30E-EDB6-49E2-B232-669B1AF7F11FQ40772358-31DC33DC-8483-4020-A2ED-4A9E95B44B62Q42231206-81FBB579-2632-430B-BDA9-3FC970CE9F46Q48076685-90C8EE8D-B8BA-42CF-9ADF-165758D308F3Q48247354-E24B7F1D-8BF8-459D-9E2D-906B6189DDF8Q48298127-A3AC7642-3F3C-4D52-87BA-BDD196640C29Q59127470-B6C7902A-14C7-4855-B8AA-862748CC2F0E
P2860
Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Unexpected effect of rifampin ...... ches to explain its mechanism.
@en
Unexpected effect of rifampin ...... ches to explain its mechanism.
@nl
type
label
Unexpected effect of rifampin ...... ches to explain its mechanism.
@en
Unexpected effect of rifampin ...... ches to explain its mechanism.
@nl
prefLabel
Unexpected effect of rifampin ...... ches to explain its mechanism.
@en
Unexpected effect of rifampin ...... ches to explain its mechanism.
@nl
P2093
P2860
P356
P1476
Unexpected effect of rifampin ...... ches to explain its mechanism.
@en
P2093
Bharat Damle
Kenny Lian
Kuan Gandelman
Odette A Fahmi
R Scott Obach
P2860
P304
P356
10.1177/0091270010366445
P50
P577
2010-04-06T00:00:00Z